SCHEMBL5654556

SCHEMBL5654556

CCOc1cc(C(=O)NCCCN(CC)CC)ccc1-c1nc2cccc(C)c2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
HTT P42858 3/20 0.42
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 2/20 0.42
TSHR P16473 1/20 0.40
IGF1R P08069 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RECQL P46063 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
USP7 Q93009 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NAMPT P43490 2/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649700 0.92 PRMT5 (0.42) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5650419 0.89 TP53 (0.46) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5648797 0.89 FLT3 (0.45) HTTSMN1; SMN2MEN1POLBKMT2A
SCHEMBL5651004 0.87 TP53 (0.44) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5651370 0.86 HPSE (0.51) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5652434 0.85 PRMT5 (0.41) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5653304 0.84 HDAC6 (0.47) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5648976 0.84 PRMT5 (0.49) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5652463 0.83 HTT (0.45) PRMT5WDR77HTTTP53SMN1; SMN2
SCHEMBL5652453 0.83 HTT (0.45) PRMT5WDR77HTTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PRMT5 448/4885WDR77 1101/4885HTT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.